Category - Markets

Markets

Leerink starts Inspire Medical at OP; PT $57

Leerink launched coverage of Inspire Medical Systems (NYSE:INSP) with an “outperform” rating and $57 price target. The stock closed at $40 on Oct. 26. “We see Inspire as a sustainable ultra high-growth/gross margin...

October 29, 2018

Markets

Stifel starts IRIDEX at buy; PT $9

Stifel initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and price target of $9. The stock closed at $5.40 on Oct. 25. IRIDEX is a leader in developing, manufacturing, and marketing laser-based medical...

October 26, 2018

Markets

Ladenburg starts Athenex at buy; PT $27

Ladenburg Thalmann launched coverage of Athenex (NASDAQ:ATNX) with a “buy” rating and $27 price target. The stock closed at $12.37 on Oct. 24. Athenex is focused on the development and commercialization of novel...

October 25, 2018

Markets

HCW starts Autolus Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...

October 24, 2018

Markets

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

October 23, 2018

Markets

Piper Jaffray starts Ra Medical at OW; PT $23

Piper Jaffray initiated coverage of Ra Medical Systems (NASDAQ:RMED) with an “overweight” rating and price target of $23. The stock closed at $13.25 on Oct. 19. Ra makes and sells excimer laser products. While it has a...

October 22, 2018

Markets

Titan Pharma shares jump 33% on initiation by A.G.P.

Shares of Titan Pharmaceuticals (NASDAQ:TTNP) jumped 33% to close at 32 cents on Oct. 18 after A.G.P./Alliance Global Partners initiated coverage of Titan with a “buy” rating and price target of 45 cents. Turnover was a...

October 19, 2018

Markets

BTIG starts Y-mAbs Therapeutics at buy; PT $35

BTIG launched coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and $35 price target. The stock closed at $21.60 on Oct. 15. Y-mAbs is in pivotal trials for the treatment of both primary neuroblastomas...

October 16, 2018

Markets

Stifel starts KalVista Pharma at buy; PT $33

Stifel initiated coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $33 price target. The stock closed at $18.76 on Oct. 12. “Our bullish thesis on the stock centers around lead asset, KVD900, an...

October 15, 2018

Markets

HCW ups Vascular Biogenics to buy; PT $3

H.C. Wainwright upgraded Vascular Biogenics (NASDAQ:VBLT) to “buy” from “neutral” but maintained its $3 price target, citing a 46% stock price decline since March, despite no negative news. The stock closed at $1.42 on...

October 15, 2018

Category - Markets

Subscribe